EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Comparison of the Effectiveness and Hypocalcemia Risk of Antiresorptive Agents in Patients with Hypercalcemia of Malignancy

Sung Hye Kong, Seung Shin Park, Jung Hee Kim, Sang Wan Kim, Se Hyun Kim, Jee Hyun Kim, Chan Soo Shin

Endocrinology and Metabolism · 2025

DOI: 10.3803/enm.2024.2132 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Endocrinology and Metabolism, 2025. Verfasst von Sung Hye Kong und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University Coll…. Hauptthemen laut MEDLINE: Hypocalcemia, Hypercalcemia, Denosumab, Bone Density Conservation Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hypercalcemia of malignancy (HCM), a major metabolic complication of cancer, is often managed with bisphosphonates (BP) and, increasingly, with denosumab. We aimed to compare the effectiveness and safety of denosumab with that of BP, with or without calcitonin, in treating HCM.

Methods

This retrospective cohort study was conducted at a tertiary hospital from 2017 to 2022 and included 317 patients treated for HCM. Participants were divided into three treatment groups: denosumab, intravenous (IV) BP only, and IV BP combined with calcitonin. The primary outcomes measured were changes in calcium levels and the incidence of hypocalcemia. Analysis of covariance was used to adjust for age, sex, body mass index, creatinine level, type of malignancy, and the use of furosemide and steroids.

Results

The mean participant age was 65 years, and 37.5% were female. After adjustment, both denosumab and IV BPs were found to effectively lower calcium levels. Denosumab led to a decrease of 2.0 mg/dL (−15.9%), while IV BP alone resulted in a reduction of 1.8 mg/dL (−13.9%). The largest reduction, of 2.7 mg/dL (−20.9%), occurred with IV BP and calcitonin. Both denosumab and IV BP+calcitonin yielded their lowest calcium levels within 48 hours, whereas the IV BP only group reached a nadir within 72 hours. Despite these differences in treatment effectiveness, hypocalcemia occurred significantly less frequently in the denosumab group compared to the other groups.

Conclusion

Denosumab and IV BP were similarly effective in reducing calcium levels. However, IV BP combined with calcitonin yielded a more rapid and pronounced decrease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypocalcemiaHypercalcemiaDenosumabBone Density Conservation AgentsDiphosphonatesNeoplasmsHumansFemaleMaleRetrospective StudiesAgedMiddle AgedCalcitoninCalciumPrognosisFollow-Up StudiesTreatment Outcome

Stichwörter der Autor:innen

CalcitoninDenosumabDiphosphonatesHypercalcemiaSafetyTreatment outcome

Substanzen

DenosumabBone Density Conservation AgentsDiphosphonatesCalcitoninCalcium

Autor:innen und Institutionen

  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea.
  • Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.

Zitieren

APA

Kong, S. H., Park, S. S., Kim, J. H., Kim, S. W., Kim, S. H., Kim, J. H., & Shin, C. S. (2025). Comparison of the Effectiveness and Hypocalcemia Risk of Antiresorptive Agents in Patients with Hypercalcemia of Malignancy. Endocrinology and Metabolism. https://doi.org/10.3803/enm.2024.2132

Vancouver

Kong SH, Park SS, Kim JH, Kim SW, Kim SH, Kim JH, et al. Comparison of the Effectiveness and Hypocalcemia Risk of Antiresorptive Agents in Patients with Hypercalcemia of Malignancy. Endocrinology and Metabolism. 2025. doi:10.3803/enm.2024.2132

BibTeX
@article{Kong2025,
  author = {Kong, Sung Hye and Park, Seung Shin and Kim, Jung Hee and Kim, Sang Wan and Kim, Se Hyun and Kim, Jee Hyun and Shin, Chan Soo},
  title = {Comparison of the Effectiveness and Hypocalcemia Risk of Antiresorptive Agents in Patients with Hypercalcemia of Malignancy},
  journal = {Endocrinology and Metabolism},
  year = {2025},
  doi = {10.3803/enm.2024.2132}
}
Kostenlos starten →